Finerenone and quality of life in heart failure: component-level analyses and clinical relevance of the Kansas City cardiomyopathy questionnaire.

Eur J Heart FailSep 15, 2026
Clinical ResearchCardiology

Yasuhiro Hamatani, Alexander Peikert, Brian L Claggett et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial, part of the FINEARTS-HF study, evaluated the effects of finerenone on health status in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Among 5006 participants, finerenone improved most Kansas City Cardiomyopathy Questionnaire (KCCQ) components, with notable enhancements in lower limb oedema frequency (+2.5) and fatigue burden (+2.2).

Key findings

  • Finerenone improved lower limb oedema frequency by +2.5 (95% CI: 0.9-4.1) compared to placebo.
  • Fatigue burden increased by +2.2 (95% CI: 0.9-3.5) with finerenone treatment.
  • KCCQ-overall summary score (OSS) at 12 months was inversely related to age, with a shift of 4.7 years (95% CI: 0.4-9.1).
  • Finerenone numerically improved all but one KCCQ component.

Why it matters

Understanding the impact of finerenone on specific health status components can help clinicians better address patient concerns and improve quality of life in those with HFmrEF/HFpEF.

Source

PubMed · PMID 41817207

Published in Eur J Heart Fail. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.